Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Helsinki - Delayed Quote EUR

Biohit Oyj (BIOBV.HE)

2.5520
-0.0250
(-0.97%)
At close: 6:12:53 PM GMT+3

Key Executives

Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
NameTitlePayExercisedYear Born
Prof. Osmo Antero Suovaniemi M.D., Ph.D. Founder, Deputy CEO, Member of Scientific Advisory Board & Director -- -- 1943
Mr. Jussi Hahtela President & CEO -- -- 1973
Mr. Jussi Sorvo Chief Financial Officer -- -- 1990
Mr. Panu Hendolin Ph.D. Chief Technology Officer -- -- 1971
Graham Johnson B.Sc., BSc Head of Global Sales & Marketing -- -- --
Mr. Yulia Kubacheva Head of Diagnostics Department - Biohit Russia -- -- --

Biohit Oyj

Laippatie 1
Helsinki, 00880
Finland
358 9 773 861 https://www.biohithealthcare.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
46

Description

Biohit Oyj, a biotechnology company, manufactures and sells bind acetaldehyde, diagnostic products, and systems for diagnostic analysis for the use of research institutions, healthcare, and industry worldwide. The company's diagnostic tests product includes the GastroPanel Unified test panel for stomach health check; GastroPanel Four-in-One stomach test; GastroSoft software application to assist clinicians and general practitioner; BIOHIT Active B12, a test for measuring the concentration of total vitamin-B12 in the serum; BIOHIT Total 25OH Vitamin D, a test for determination of 25-hydroxyvitamin D2 and D3; and BIOHIT Calprotectin test, a quantitative test that provides a reliable differentiation between inflammatory bowel diseases and irritable bowel syndrome. It also offers GastroPanel quick test NT, a quantitative immunochromatographic test for the detection of Helicobacter pylori (H. Pylori) and atrophic gastritis; BIOHIT Celiac Quick test for diagnosis of celiac disease; Biohit ColonView Quick test, a test for detection of fecal occult blood; Biohit Helicobacter Pylori UFT300 and Helicobacter Pylori Quick test methods to detect H. pylori infection; Gluten Immunogenic Peptides test; and Lactose Intolerance quick test to support the diagnosis of lactose intolerance in a duodenal biopsy specimen. The company provides acetaldehyde-binding products, such as Acetium capsules for protection of stomach; Acetium lozenge, which helps in quitting smoking; and monoclonal antibodies for use in the areas of cellular pathology, neurobiology, oncology, and human gastric biomarkers research. It also offers BIOHIT FAEX for the collection and handling of stool samples; and GP Reader NT, an automated instrument for the quantitative determination of various analytes in human samples, such as whole blood, plasma, or fecal samples by measuring fluorescence signals from lateral flow test cassettes. The company was incorporated in 1988 and is headquartered in Helsinki, Finland.

Corporate Governance

Biohit Oyj’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events

April 15, 2014 at 12:00 AM UTC

Ex-Dividend Date

Related Tickers